Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
70 hedge funds and large institutions have $69.8M invested in Adverum Biotechnologies in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2.23% more ownership
Funds ownership: 76.32% → 78.54% (+2.2%)
1% more funds holding
Funds holding: 69 → 70 (+1)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less capital invested
Capital invested by funds: $74.1M → $69.8M (-$4.32M)
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
33% less call options, than puts
Call options by funds: $28K | Put options by funds: $42K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.14M |
| 2 |
PWA
Principia Wealth Advisory
Dallas,
Texas
|
+$1.65M |
| 3 |
WA
Waverly Advisors
Birmingham,
Alabama
|
+$722K |
| 4 |
GWA
GGM Wealth Advisors
Baltimore,
Maryland
|
+$342K |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$672K |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$634K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$458K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$348K |
| 5 |
BlackRock
New York
|
-$263K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$85.3K | -18,261 | Closed |
|
77
HSBC Holdings
London,
United Kingdom
| – | -$48.7K | -10,704 | Closed |
|
|
RS
78
R Squared
Central,
Hong Kong
| – | -$3.32K | -710 | Closed |
|
|
CIAM
79
Caitong International Asset Management
Hong Kong
| – | -$205 | -44 | Closed |
|
ADVM Hedge Fund Activity: Q1 2025 in Review
70 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2025, worth a combined $69.8M — down 5.8% from $74.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ADVM positions and 9 closed out — a net gain of 1 holder — while 18 added to existing stakes and 23 trimmed.
The largest buyer was BML Capital Management, adding an estimated $2.14M. The largest seller was Citadel Advisors, exiting entirely with an estimated $672K sold.
- 70 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2025, up from 69 in Q4 2024.
- Funds reported $69.8M of Adverum Biotechnologies stock for Q1 2025, down 5.8% quarter-over-quarter.
- 10 funds opened new Adverum Biotechnologies positions in Q1 2025 and 9 closed out, a net change of +1 holder.
- The largest Adverum Biotechnologies buyer in Q1 2025 was BML Capital Management, an estimated $2.14M added.
- The largest Adverum Biotechnologies seller in Q1 2025 was Citadel Advisors, an estimated $672K sold.
Based on aggregated 13F filings for Q1 2025.